Up next

Autoplay

FDA Approves Dabigatran

0 Views • 08/18/25
Share
Side Effects
Side Effects
Subscribers
0

The FDA recently approved the oral thrombin inhibitor dabigatran (Pradaxa) for the prevention of stroke or systemic embolism. The approval was based on the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, which found that dabigatran, an agent that does not require monitoring of the INR, was as safe and effective, and at the 150-mg twice daily dose, actually superior to warfarin. Read Dr. Christopher Cannon's blog post on the approval at: http://blog.cardiosource.org/post/Dabigatran.aspx.

Show more
0 Comments sort Sort By

Up next

Autoplay